富士胶片：大型生物制药生产基地：在美国新成立
2021年1月7日
富士胶卷：
我们将进行超过2000亿日元的大规模投资。
在美国建立了大型生物制药生产基地。
支持大量生产API，
从原料药生产到配方，
一站式一站式包装合同
富士Diosynth生物技术：
FUJIFILM Diosynth Biotechnologies（FDB），生物制药CDMO的核心公司（* 2）
新基地将于2025年春季投入运营。
富士胶卷：
目前，我们正在4个FDB基地开展业务。
美国（德克萨斯州北卡罗莱纳州）
英国（比林汉姆市）
在丹麦（希尔德城）
我们正在扩大生物制药的合同开发和制造业务。
生物制药生产：
抗体药物和激素制剂，
基因治疗药
疫苗等
我们将开发所有类型生物制药的生产工艺，并利用我们的优势来处理从原料药到配方和包装的合同制造。
日本经济新闻
https://www.nikkei.com/article/DGXLRSP602770_X00C21A1000000/
Fujifilm to Invest Over 200 Billion yen (2 Billion USD) to Establish New Large-Scale Cell Culture Manufacturing Site for Biopharmaceuticals in the U.S.A.
TOKYO, January 7, 2021
FUJIFILM Corporation (President: Kenji Sukeno)
is making an investment of more than 200 Billion yen (2 Billion USD) to establish a new large-scale cell culture production site in the United States to accelerate the growth of its biopharmaceutical contract development and manufacturing business (CDMO).
FUJIFILM Diosynth Biotechnologies,
a subsidiary of FUJIFILM Corporation,
with development and manufacturing facilities across the U.S.A., U.K., and Denmark will operate the new facility.
This new facility
will offer large-scale cell culture manufacturing of bulk drug substance with 8 x 20,000L bioreactors (physical volume), with the potential to expand and add a further 24 x 20,000L bioreactors based on market demand.
In addition to drug substance manufacture, the facility
will also provide commercial scale, automated fill-finish and assembly, packaging and labeling services.
The new site
will be built within the vicinity of an existing Fujifilm site, and is scheduled to begin operations in the spring of 2025.
Fujifilm Global